BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tokarew N, Ogonek J, Endres S, von Bergwelt-Baildon M, Kobold S. Teaching an old dog new tricks: next-generation CAR T cells. Br J Cancer 2019;120:26-37. [PMID: 30413825 DOI: 10.1038/s41416-018-0325-1] [Cited by in Crossref: 81] [Cited by in F6Publishing: 69] [Article Influence: 20.3] [Reference Citation Analysis]
Number Citing Articles
1 Fu R, Li H, Li R, Mcgrath K, Dotti G, Gu Z. Delivery Techniques for Enhancing CAR T Cell Therapy against Solid Tumors. Adv Funct Mater 2021;31:2009489. [DOI: 10.1002/adfm.202009489] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
2 Harrer DC, Dörrie J, Schaft N. CSPG4 as Target for CAR-T-Cell Therapy of Various Tumor Entities-Merits and Challenges. Int J Mol Sci 2019;20:E5942. [PMID: 31779130 DOI: 10.3390/ijms20235942] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
3 Hashemzadeh N, Dolatkhah M, Adibkia K, Aghanejad A, Barzegar-Jalali M, Omidi Y, Barar J. Recent advances in breast cancer immunotherapy: The promising impact of nanomedicines. Life Sci 2021;271:119110. [PMID: 33513401 DOI: 10.1016/j.lfs.2021.119110] [Reference Citation Analysis]
4 Götzke H, Kilisch M, Martínez-Carranza M, Sograte-Idrissi S, Rajavel A, Schlichthaerle T, Engels N, Jungmann R, Stenmark P, Opazo F, Frey S. The ALFA-tag is a highly versatile tool for nanobody-based bioscience applications. Nat Commun 2019;10:4403. [PMID: 31562305 DOI: 10.1038/s41467-019-12301-7] [Cited by in Crossref: 60] [Cited by in F6Publishing: 45] [Article Influence: 20.0] [Reference Citation Analysis]
5 Umut Ö, Gottschlich A, Endres S, Kobold S. CAR T cell therapy in solid tumors: a short review. Memo 2021;14:143-9. [PMID: 34777609 DOI: 10.1007/s12254-021-00703-7] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
6 Yadav RK, Ali A, Kumar S, Sharma A, Baghchi B, Singh P, Das S, Singh C, Sharma S. CAR T cell therapy: newer approaches to counter resistance and cost. Heliyon 2020;6:e03779. [PMID: 32322738 DOI: 10.1016/j.heliyon.2020.e03779] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
7 Arabi F, Mansouri V, Ahmadbeigi N. Gene therapy clinical trials, where do we go? An overview. Biomed Pharmacother 2022;153:113324. [PMID: 35779421 DOI: 10.1016/j.biopha.2022.113324] [Reference Citation Analysis]
8 Safarzadeh Kozani P, Safarzadeh Kozani P, Rahbarizadeh F. CAR-T cell therapy in T-cell malignancies: Is success a low-hanging fruit? Stem Cell Res Ther 2021;12:527. [PMID: 34620233 DOI: 10.1186/s13287-021-02595-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Liu M, Gao Y, Yuan Y, Shi S, Yang K, Wu J, Zhang J, Tian J. Global hotspots and future prospects of chimeric antigen receptor T-cell therapy in cancer research: a bibliometric analysis. Future Oncology 2020;16:597-612. [DOI: 10.2217/fon-2019-0810] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
10 Pich O, Bailey C, Watkins TBK, Zaccaria S, Jamal-Hanjani M, Swanton C. The translational challenges of precision oncology. Cancer Cell 2022:S1535-6108(22)00164-7. [PMID: 35487215 DOI: 10.1016/j.ccell.2022.04.002] [Reference Citation Analysis]
11 Bashiri Dezfouli A, Yazdi M, Pockley AG, Khosravi M, Kobold S, Wagner E, Multhoff G. NK Cells Armed with Chimeric Antigen Receptors (CAR): Roadblocks to Successful Development. Cells 2021;10:3390. [PMID: 34943898 DOI: 10.3390/cells10123390] [Reference Citation Analysis]
12 Pietrobon V, Todd LA, Goswami A, Stefanson O, Yang Z, Marincola F. Improving CAR T-Cell Persistence. Int J Mol Sci 2021;22:10828. [PMID: 34639168 DOI: 10.3390/ijms221910828] [Reference Citation Analysis]
13 Nash A, Aghlara-Fotovat S, Hernandez A, Scull C, Veiseh O. Clinical translation of immunomodulatory therapeutics. Adv Drug Deliv Rev 2021;176:113896. [PMID: 34324885 DOI: 10.1016/j.addr.2021.113896] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
14 Staudt RE, Carlson RD, Snook AE. Targeting gastrointestinal cancers with chimeric antigen receptor (CAR)-T cell therapy. Cancer Biology & Therapy 2022;23:127-33. [DOI: 10.1080/15384047.2022.2033057] [Reference Citation Analysis]
15 Blaeschke F, Ortner E, Stenger D, Mahdawi J, Apfelbeck A, Habjan N, Weißer T, Kaeuferle T, Willier S, Kobold S, Feuchtinger T. Design and Evaluation of TIM-3-CD28 Checkpoint Fusion Proteins to Improve Anti-CD19 CAR T-Cell Function. Front Immunol 2022;13:845499. [PMID: 35464394 DOI: 10.3389/fimmu.2022.845499] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Krishna D, Rittié L, Tran H, Zheng X, Chen-Rogers CE, McGillivray A, Clay T, Ketkar A, Tarnowski J. Short Time to Market and Forward Planning Will Enable Cell Therapies to Deliver R&D Pipeline Value. Hum Gene Ther 2021;32:433-45. [PMID: 33023309 DOI: 10.1089/hum.2020.212] [Reference Citation Analysis]
17 Giuliano A. Companion Animal Model in Translational Oncology; Feline Oral Squamous Cell Carcinoma and Canine Oral Melanoma. Biology (Basel) 2021;11:54. [PMID: 35053051 DOI: 10.3390/biology11010054] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
18 Traba J, Sack MN, Waldmann TA, Anton OM. Immunometabolism at the Nexus of Cancer Therapeutic Efficacy and Resistance. Front Immunol 2021;12:657293. [PMID: 34079545 DOI: 10.3389/fimmu.2021.657293] [Reference Citation Analysis]
19 Xin T, Cheng L, Zhou C, Zhao Y, Hu Z, Wu X. In-Vivo Induced CAR-T Cell for the Potential Breakthrough to Overcome the Barriers of Current CAR-T Cell Therapy. Front Oncol 2022;12:809754. [PMID: 35223491 DOI: 10.3389/fonc.2022.809754] [Reference Citation Analysis]
20 Jin KT, Chen B, Liu YY, Lan HU, Yan JP. Monoclonal antibodies and chimeric antigen receptor (CAR) T cells in the treatment of colorectal cancer. Cancer Cell Int 2021;21:83. [PMID: 33522929 DOI: 10.1186/s12935-021-01763-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
21 Fu Z, Zhou J, Chen R, Jin Y, Ni T, Qian L, Xiao C. Cluster of differentiation 19 chimeric antigen receptor T-cell therapy in pediatric acute lymphoblastic leukemia. Oncol Lett 2020;20:36. [PMID: 32802160 DOI: 10.3892/ol.2020.11897] [Reference Citation Analysis]
22 Shokouhifar A, Firouzi J, Nouri M, Sarab GA, Ebrahimi M. NK cell upraise in the dark world of cancer stem cells. Cancer Cell Int 2021;21:682. [PMID: 34923966 DOI: 10.1186/s12935-021-02400-1] [Reference Citation Analysis]
23 Abrantes R, Duarte HO, Gomes C, Wälchli S, Reis CA. CAR-Ts: new perspectives in cancer therapy. FEBS Lett 2022. [PMID: 34978080 DOI: 10.1002/1873-3468.14270] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
24 Bashiri Dezfouli A, Yazdi M, Benmebarek MR, Schwab M, Michaelides S, Miccichè A, Geerts D, Stangl S, Klapproth S, Wagner E, Kobold S, Multhoff G. CAR T Cells Targeting Membrane-Bound Hsp70 on Tumor Cells Mimic Hsp70-Primed NK Cells. Front Immunol 2022;13:883694. [PMID: 35720311 DOI: 10.3389/fimmu.2022.883694] [Reference Citation Analysis]
25 Aghajanian H, Rurik JG, Epstein JA. CAR-based therapies: opportunities for immuno-medicine beyond cancer. Nat Metab 2022;4:163-9. [PMID: 35228742 DOI: 10.1038/s42255-022-00537-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
26 Wu WT, Lin WY, Chen YW, Lin CF, Wang HH, Wu SH, Lee YY. New Era of Immunotherapy in Pediatric Brain Tumors: Chimeric Antigen Receptor T-Cell Therapy. Int J Mol Sci 2021;22:2404. [PMID: 33673696 DOI: 10.3390/ijms22052404] [Reference Citation Analysis]
27 Lin WY, Wang HH, Chen YW, Lin CF, Fan HC, Lee YY. Gene Modified CAR-T Cellular Therapy for Hematologic Malignancies. Int J Mol Sci 2020;21:E8655. [PMID: 33212810 DOI: 10.3390/ijms21228655] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
28 Kruger S, Ilmer M, Kobold S, Cadilha BL, Endres S, Ormanns S, Schuebbe G, Renz BW, D'Haese JG, Schloesser H, Heinemann V, Subklewe M, Boeck S, Werner J, von Bergwelt-Baildon M. Advances in cancer immunotherapy 2019 - latest trends. J Exp Clin Cancer Res 2019;38:268. [PMID: 31217020 DOI: 10.1186/s13046-019-1266-0] [Cited by in Crossref: 164] [Cited by in F6Publishing: 156] [Article Influence: 54.7] [Reference Citation Analysis]
29 Safarzadeh Kozani P, Safarzadeh Kozani P, Rahbarizadeh F. Addressing the obstacles of CAR T cell migration in solid tumors: wishing a heavy traffic. Crit Rev Biotechnol 2021;:1-20. [PMID: 34957875 DOI: 10.1080/07388551.2021.1988509] [Reference Citation Analysis]
30 Luangwattananun P, Junking M, Sujjitjoon J, Wutti-In Y, Poungvarin N, Thuwajit C, Yenchitsomanus PT. Fourth-generation chimeric antigen receptor T cells targeting folate receptor alpha antigen expressed on breast cancer cells for adoptive T cell therapy. Breast Cancer Res Treat 2021;186:25-36. [PMID: 33389403 DOI: 10.1007/s10549-020-06032-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
31 Baci D, Bosi A, Gallazzi M, Rizzi M, Noonan DM, Poggi A, Bruno A, Mortara L. The Ovarian Cancer Tumor Immune Microenvironment (TIME) as Target for Therapy: A Focus on Innate Immunity Cells as Therapeutic Effectors. Int J Mol Sci 2020;21:E3125. [PMID: 32354198 DOI: 10.3390/ijms21093125] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
32 Zheng Y, Nandakumar KS, Cheng K. Optimization of CAR-T Cell-Based Therapies Using Small-Molecule-Based Safety Switches. J Med Chem 2021;64:9577-91. [PMID: 34191515 DOI: 10.1021/acs.jmedchem.0c02054] [Reference Citation Analysis]
33 Timmers M, Roex G, Wang Y, Campillo-Davo D, Van Tendeloo VFI, Chu Y, Berneman ZN, Luo F, Van Acker HH, Anguille S. Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen. Front Immunol 2019;10:1613. [PMID: 31379824 DOI: 10.3389/fimmu.2019.01613] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 13.0] [Reference Citation Analysis]
34 Xie M, Viviani M, Fussenegger M. Engineering precision therapies: lessons and motivations from the clinic. Synth Biol (Oxf) 2021;6:ysaa024. [PMID: 33817342 DOI: 10.1093/synbio/ysaa024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
35 Marhelava K, Krawczyk M, Firczuk M, Fidyt K. CAR-T Cells Shoot for New Targets: Novel Approaches to Boost Adoptive Cell Therapy for B Cell-Derived Malignancies. Cells 2022;11:1804. [DOI: 10.3390/cells11111804] [Reference Citation Analysis]
36 Davis AP, Kao SC, Clarke SJ, Boyer M, Pavlakis N. Emerging biological therapies for the treatment of malignant pleural mesothelioma. Expert Opin Emerg Drugs 2021;26:179-92. [PMID: 33945357 DOI: 10.1080/14728214.2021.1924670] [Reference Citation Analysis]
37 Magnani CF, Tettamanti S, Alberti G, Pisani I, Biondi A, Serafini M, Gaipa G. Transposon-Based CAR T Cells in Acute Leukemias: Where are We Going? Cells 2020;9:E1337. [PMID: 32471151 DOI: 10.3390/cells9061337] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
38 Keane JT, Posey AD Jr. Chimeric Antigen Receptors Expand the Repertoire of Antigenic Macromolecules for Cellular Immunity. Cells 2021;10:3356. [PMID: 34943864 DOI: 10.3390/cells10123356] [Reference Citation Analysis]
39 Banerjee R, Shah N, Dicker AP. Next-Generation Implementation of Chimeric Antigen Receptor T-Cell Therapy Using Digital Health. JCO Clin Cancer Inform 2021;5:668-78. [PMID: 34110929 DOI: 10.1200/CCI.21.00023] [Reference Citation Analysis]
40 Lee NS, Yoon CW, Wang Q, Moon S, Koo KM, Jung H, Chen R, Jiang L, Lu G, Fernandez A, Chow RH, Weitz AC, Salvaterra PM, Pinaud F, Shung KK. Focused Ultrasound Stimulates ER Localized Mechanosensitive PANNEXIN-1 to Mediate Intracellular Calcium Release in Invasive Cancer Cells. Front Cell Dev Biol 2020;8:504. [PMID: 32656213 DOI: 10.3389/fcell.2020.00504] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
41 López-Cantillo G, Urueña C, Camacho BA, Ramírez-Segura C. CAR-T Cell Performance: How to Improve Their Persistence? Front Immunol 2022;13:878209. [PMID: 35572525 DOI: 10.3389/fimmu.2022.878209] [Reference Citation Analysis]
42 Franklin MR, Platero S, Saini KS, Curigliano G, Anderson S. Immuno-oncology trends: preclinical models, biomarkers, and clinical development. J Immunother Cancer 2022;10:e003231. [PMID: 35022192 DOI: 10.1136/jitc-2021-003231] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
43 Stoiber S, Cadilha BL, Benmebarek MR, Lesch S, Endres S, Kobold S. Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy. Cells 2019;8:E472. [PMID: 31108883 DOI: 10.3390/cells8050472] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 17.3] [Reference Citation Analysis]
44 Tian Y, Li Y, Shao Y, Zhang Y. Gene modification strategies for next-generation CAR T cells against solid cancers. J Hematol Oncol 2020;13:54. [PMID: 32423475 DOI: 10.1186/s13045-020-00890-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 10.5] [Reference Citation Analysis]
45 Tan JY, Low MH, Chen Y, Lim FLWI. CAR T Cell Therapy in Hematological Malignancies: Implications of the Tumor Microenvironment and Biomarkers on Efficacy and Toxicity. IJMS 2022;23:6931. [DOI: 10.3390/ijms23136931] [Reference Citation Analysis]
46 Safarzadeh Kozani P, Safarzadeh Kozani P, Rahbarizadeh F, Khoshtinat Nikkhoi S. Strategies for Dodging the Obstacles in CAR T Cell Therapy. Front Oncol 2021;11:627549. [PMID: 33869011 DOI: 10.3389/fonc.2021.627549] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 9.0] [Reference Citation Analysis]
47 Lesch S, Blumenberg V, Stoiber S, Gottschlich A, Ogonek J, Cadilha BL, Dantes Z, Rataj F, Dorman K, Lutz J, Karches CH, Heise C, Kurzay M, Larimer BM, Grassmann S, Rapp M, Nottebrock A, Kruger S, Tokarew N, Metzger P, Hoerth C, Benmebarek MR, Dhoqina D, Grünmeier R, Seifert M, Oener A, Umut Ö, Joaquina S, Vimeux L, Tran T, Hank T, Baba T, Huynh D, Megens RTA, Janssen KP, Jastroch M, Lamp D, Ruehland S, Di Pilato M, Pruessmann JN, Thomas M, Marr C, Ormanns S, Reischer A, Hristov M, Tartour E, Donnadieu E, Rothenfusser S, Duewell P, König LM, Schnurr M, Subklewe M, Liss AS, Halama N, Reichert M, Mempel TR, Endres S, Kobold S. T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours. Nat Biomed Eng 2021. [PMID: 34083764 DOI: 10.1038/s41551-021-00737-6] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
48 Dai K, Wu Y, She S, Zhang Q. Advancement of chimeric antigen receptor-natural killer cells targeting hepatocellular carcinoma. World J Gastrointest Oncol 2021; 13(12): 2029-2037 [DOI: 10.4251/wjgo.v13.i12.2029] [Reference Citation Analysis]
49 Huang Z, Wu Y, Allen ME, Pan Y, Kyriakakis P, Lu S, Chang YJ, Wang X, Chien S, Wang Y. Engineering light-controllable CAR T cells for cancer immunotherapy. Sci Adv 2020;6:eaay9209. [PMID: 32128416 DOI: 10.1126/sciadv.aay9209] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 14.0] [Reference Citation Analysis]
50 Cheng G, Dong H, Yang C, Liu Y, Wu Y, Zhu L, Tong X, Wang S. A review on the advances and challenges of immunotherapy for head and neck cancer. Cancer Cell Int 2021;21:406. [PMID: 34332576 DOI: 10.1186/s12935-021-02024-5] [Reference Citation Analysis]
51 Schwerdtfeger M, Benmebarek MR, Endres S, Subklewe M, Desiderio V, Kobold S. Chimeric Antigen Receptor-Modified T Cells and T Cell-Engaging Bispecific Antibodies: Different Tools for the Same Job. Curr Hematol Malig Rep 2021;16:218-33. [PMID: 33939108 DOI: 10.1007/s11899-021-00628-2] [Reference Citation Analysis]
52 Wang LL, Janes ME, Kumbhojkar N, Kapate N, Clegg JR, Prakash S, Heavey MK, Zhao Z, Anselmo AC, Mitragotri S. Cell therapies in the clinic. Bioeng Transl Med 2021;6:e10214. [PMID: 34027097 DOI: 10.1002/btm2.10214] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
53 King C. CAR NK Cell Therapy for T Follicular Helper Cells. Cell Rep Med 2020;1:100009. [PMID: 33205057 DOI: 10.1016/j.xcrm.2020.100009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
54 Arndt C, Fasslrinner F, Loureiro LR, Koristka S, Feldmann A, Bachmann M. Adaptor CAR Platforms-Next Generation of T Cell-Based Cancer Immunotherapy. Cancers (Basel) 2020;12:E1302. [PMID: 32455621 DOI: 10.3390/cancers12051302] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
55 Lee BK, Wan Y, Chin ZL, Deng L, Deng M, Leung TM, Hua J, Zhang H. Developing ROR1 Targeting CAR-T Cells against Solid Tumors in Preclinical Studies. Cancers (Basel) 2022;14:3618. [PMID: 35892876 DOI: 10.3390/cancers14153618] [Reference Citation Analysis]
56 Schanda N, Sauer T, Kunz A, Hückelhoven-Krauss A, Neuber B, Wang L, Hinkelbein M, Sedloev D, He B, Schubert ML, Müller-Tidow C, Schmitt M, Schmitt A. Sensitivity and Specificity of CD19.CAR-T Cell Detection by Flow Cytometry and PCR. Cells 2021;10:3208. [PMID: 34831430 DOI: 10.3390/cells10113208] [Reference Citation Analysis]
57 Xue T, Zhao X, Zhao K, Lu Y, Yao J, Ji X. Immunotherapy for lung cancer: Focusing on chimeric antigen receptor (CAR)-T cell therapy. Curr Probl Cancer 2021;:100791. [PMID: 34538649 DOI: 10.1016/j.currproblcancer.2021.100791] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Kandra P, Nandigama R, Eul B, Huber M, Kobold S, Seeger W, Grimminger F, Savai R. Utility and Drawbacks of Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Lung Cancer. Front Immunol 2022;13:903562. [PMID: 35720364 DOI: 10.3389/fimmu.2022.903562] [Reference Citation Analysis]
59 Belderbos RA, Vroman H, Aerts JGJV. Cellular Immunotherapy and Locoregional Administration of CAR T-Cells in Malignant Pleural Mesothelioma. Front Oncol 2020;10:777. [PMID: 32582537 DOI: 10.3389/fonc.2020.00777] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
60 El-Khazragy N, Ghozy S, Emad P, Mourad M, Razza D, Farouk YK, Mohamed NA, Ahmed MK, Youssef T, Bahnasawy YM, Elmasery S. Chimeric antigen receptor T cells immunotherapy: challenges and opportunities in hematological malignancies. Immunotherapy 2020;12:1341-57. [PMID: 33148070 DOI: 10.2217/imt-2020-0181] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
61 Klampatsa A, Dimou V, Albelda SM. Mesothelin-targeted CAR-T cell therapy for solid tumors. Expert Opin Biol Ther 2021;21:473-86. [PMID: 33176519 DOI: 10.1080/14712598.2021.1843628] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
62 Saleh OM, Albakri KA, Alabdallat YJ, Dajani MH, El Gazzar WB. The safety and efficacy of CAR-T cells in the treatment of prostate cancer: review. Biomarkers 2021;:1-13. [PMID: 34882051 DOI: 10.1080/1354750X.2021.2016973] [Reference Citation Analysis]
63 Springuel L, Lonez C, Alexandre B, Van Cutsem E, Machiels JH, Van Den Eynde M, Prenen H, Hendlisz A, Shaza L, Carrasco J, Canon JL, Opyrchal M, Odunsi K, Rottey S, Gilham DE, Flament A, Lehmann FF. Chimeric Antigen Receptor-T Cells for Targeting Solid Tumors: Current Challenges and Existing Strategies. BioDrugs 2019;33:515-37. [PMID: 31363930 DOI: 10.1007/s40259-019-00368-z] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 11.5] [Reference Citation Analysis]
64 Cella F, Siciliano V. Protein-based parts and devices that respond to intracellular and extracellular signals in mammalian cells. Curr Opin Chem Biol 2019;52:47-53. [PMID: 31158655 DOI: 10.1016/j.cbpa.2019.04.014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
65 Chen K, Wang S, Qi D, Ma P, Fang Y, Jiang N, Wu E, Li N. Clinical Investigations of CAR-T Cell Therapy for Solid Tumors. Front Immunol 2022;13:896685. [DOI: 10.3389/fimmu.2022.896685] [Reference Citation Analysis]
66 Soltantoyeh T, Akbari B, Karimi A, Mahmoodi Chalbatani G, Ghahri-Saremi N, Hadjati J, Hamblin MR, Mirzaei HR. Chimeric Antigen Receptor (CAR) T Cell Therapy for Metastatic Melanoma: Challenges and Road Ahead. Cells 2021;10:1450. [PMID: 34207884 DOI: 10.3390/cells10061450] [Reference Citation Analysis]
67 Alhabbab RY. Targeting Cancer Stem Cells by Genetically Engineered Chimeric Antigen Receptor T Cells. Front Genet 2020;11:312. [PMID: 32391048 DOI: 10.3389/fgene.2020.00312] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
68 Rad S M AH, Halpin JC, Mollaei M, Smith Bell SWJ, Hirankarn N, McLellan AD. Metabolic and Mitochondrial Functioning in Chimeric Antigen Receptor (CAR)-T Cells. Cancers (Basel) 2021;13:1229. [PMID: 33799768 DOI: 10.3390/cancers13061229] [Reference Citation Analysis]
69 Kooragayala K, Lou J, Hong YK. Current State of Cell Therapies for Gastrointestinal Cancers. Cancer J 2022;28:310-21. [PMID: 35880941 DOI: 10.1097/PPO.0000000000000611] [Reference Citation Analysis]
70 Grywalska E, Sosnowska-Pasiarska B, Smok-Kalwat J, Pasiarski M, Niedźwiedzka-Rystwej P, Roliński J. Paving the Way toward Successful Multiple Myeloma Treatment: Chimeric Antigen Receptor T-Cell Therapy. Cells 2020;9:E983. [PMID: 32316105 DOI: 10.3390/cells9040983] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
71 Guo X, Shen W. Latest evidence on immunotherapy for cholangiocarcinoma.Oncol Lett. 2020;20:381. [PMID: 33154779 DOI: 10.3892/ol.2020.12244] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
72 Razavi A, Keshavarz-Fathi M, Pawelek J, Rezaei N. Chimeric antigen receptor T-cell therapy for melanoma. Expert Rev Clin Immunol 2021;17:209-23. [PMID: 33481629 DOI: 10.1080/1744666X.2021.1880895] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
73 Dasyam N, George P, Weinkove R. Chimeric antigen receptor T-cell therapies: Optimising the dose. Br J Clin Pharmacol 2020;86:1678-89. [PMID: 32175617 DOI: 10.1111/bcp.14281] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
74 Glienke W, Dragon AC, Zimmermann K, Martyniszyn-eiben A, Mertens M, Abken H, Rossig C, Altvater B, Aleksandrova K, Arseniev L, Kloth C, Stamopoulou A, Moritz T, Lode HN, Siebert N, Blasczyk R, Goudeva L, Schambach A, Köhl U, Eiz-vesper B, Esser R. GMP-Compliant Manufacturing of TRUCKs: CAR T Cells targeting GD2 and Releasing Inducible IL-18. Front Immunol 2022;13:839783. [DOI: 10.3389/fimmu.2022.839783] [Reference Citation Analysis]
75 Mehrabadi AZ, Ranjbar R, Farzanehpour M, Shahriary A, Dorostkar R, Hamidinejad MA, Ghaleh HEG. Therapeutic potential of CAR T cell in malignancies: A scoping review. Biomed Pharmacother 2021;146:112512. [PMID: 34894519 DOI: 10.1016/j.biopha.2021.112512] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
76 Akhoundi M, Mohammadi M, Sahraei SS, Sheykhhasan M, Fayazi N. CAR T cell therapy as a promising approach in cancer immunotherapy: challenges and opportunities. Cell Oncol (Dordr) 2021;44:495-523. [PMID: 33759063 DOI: 10.1007/s13402-021-00593-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
77 George LL, Deshpande SR, Cortese MJ, Kendall EK, Chattaraj A, Shah Z, Zhao J, Anwer F. Emerging Targets and Cellular Therapy for Relapsed Refractory Multiple Myeloma: A Systematic Review. Clin Lymphoma Myeloma Leuk 2021:S2152-2650(21)00208-1. [PMID: 34253497 DOI: 10.1016/j.clml.2021.06.003] [Reference Citation Analysis]
78 Abolarinwa BA, Ibrahim RB, Huang YH. Conceptual Development of Immunotherapeutic Approaches to Gastrointestinal Cancer. Int J Mol Sci 2019;20:E4624. [PMID: 31540435 DOI: 10.3390/ijms20184624] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
79 Wagner JC, Tang Q. CAR-Tregs as a Strategy for Inducing Graft Tolerance. Curr Transplant Rep 2020;7:205-14. [PMID: 33816057 DOI: 10.1007/s40472-020-00285-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
80 Yoshida K, Okamoto M, Aoki K, Takahashi J, Saito N. A Review of T-Cell Related Therapy for Osteosarcoma. Int J Mol Sci 2020;21:E4877. [PMID: 32664248 DOI: 10.3390/ijms21144877] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
81 Darowski D, Kobold S, Jost C, Klein C. Combining the best of two worlds: highly flexible chimeric antigen receptor adaptor molecules (CAR-adaptors) for the recruitment of chimeric antigen receptor T cells. MAbs 2019;11:621-31. [PMID: 30892136 DOI: 10.1080/19420862.2019.1596511] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
82 Caliendo F, Dukhinova M, Siciliano V. Engineered Cell-Based Therapeutics: Synthetic Biology Meets Immunology. Front Bioeng Biotechnol 2019;7:43. [PMID: 30937303 DOI: 10.3389/fbioe.2019.00043] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 8.7] [Reference Citation Analysis]
83 Kim DW, Cho JY. Recent Advances in Allogeneic CAR-T Cells. Biomolecules 2020;10:E263. [PMID: 32050611 DOI: 10.3390/biom10020263] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
84 Safarzadeh Kozani P, Safarzadeh Kozani P, Rahbarizadeh F. Optimizing the Clinical Impact of CAR-T Cell Therapy in B-Cell Acute Lymphoblastic Leukemia: Looking Back While Moving Forward. Front Immunol 2021;12:765097. [PMID: 34777381 DOI: 10.3389/fimmu.2021.765097] [Reference Citation Analysis]
85 Safarzadeh Kozani P, Naseri A, Mirarefin SMJ, Salem F, Nikbakht M, Evazi Bakhshi S, Safarzadeh Kozani P. Nanobody-based CAR-T cells for cancer immunotherapy. Biomark Res 2022;10:24. [PMID: 35468841 DOI: 10.1186/s40364-022-00371-7] [Reference Citation Analysis]
86 Benmebarek MR, Karches CH, Cadilha BL, Lesch S, Endres S, Kobold S. Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells. Int J Mol Sci. 2019;20. [PMID: 30875739 DOI: 10.3390/ijms20061283] [Cited by in Crossref: 93] [Cited by in F6Publishing: 90] [Article Influence: 31.0] [Reference Citation Analysis]
87 Erfanian N, Derakhshani A, Nasseri S, Fereidouni M, Baradaran B, Jalili Tabrizi N, Brunetti O, Bernardini R, Silvestris N, Safarpour H. Immunotherapy of cancer in single-cell RNA sequencing era: A precision medicine perspective. Biomed Pharmacother 2021;146:112558. [PMID: 34953396 DOI: 10.1016/j.biopha.2021.112558] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
88 McCue AC, Yao Z, Kuhlman B. Advances in modular control of CAR-T therapy with adapter-mediated CARs. Adv Drug Deliv Rev 2022;187:114358. [PMID: 35618140 DOI: 10.1016/j.addr.2022.114358] [Reference Citation Analysis]
89 Mansouri V, Yazdanpanah N, Rezaei N. The immunologic aspects of cytokine release syndrome and graft versus host disease following CAR T cell therapy. Int Rev Immunol 2021;:1-20. [PMID: 34607523 DOI: 10.1080/08830185.2021.1984449] [Reference Citation Analysis]
90 Henze J, Tacke F, Hardt O, Alves F, Al Rawashdeh W. Enhancing the Efficacy of CAR T Cells in the Tumor Microenvironment of Pancreatic Cancer. Cancers (Basel) 2020;12:E1389. [PMID: 32481570 DOI: 10.3390/cancers12061389] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
91 Yu MW, Quail DF. Immunotherapy for Glioblastoma: Current Progress and Challenge. Front Immunol 2021;12:676301. [PMID: 34054867 DOI: 10.3389/fimmu.2021.676301] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
92 Bao C, Gao Q, Li LL, Han L, Zhang B, Ding Y, Song Z, Zhang R, Zhang J, Wu XH. The Application of Nanobody in CAR-T Therapy. Biomolecules 2021;11:238. [PMID: 33567640 DOI: 10.3390/biom11020238] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
93 Qu J, Mei Q, Chen L, Zhou J. Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives. Cancer Immunol Immunother 2021;70:619-31. [PMID: 33025047 DOI: 10.1007/s00262-020-02735-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
94 Massaro C, Min W, Pegtel DM, Baglio SR. Harnessing EV communication to restore antitumor immunity. Adv Drug Deliv Rev 2021;176:113838. [PMID: 34144088 DOI: 10.1016/j.addr.2021.113838] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
95 Silva EVDS, Nascente EDP, Miguel MP, Alves CEF, Moura VMBDD. Elucidating tumor immunosurveillance and immunoediting: a comprehensive review. Ciênc anim bras 2021;22:e-68544. [DOI: 10.1590/1809-6891v22e-68544] [Reference Citation Analysis]
96 Alnefaie A, Albogami S, Asiri Y, Ahmad T, Alotaibi SS, Al-sanea MM, Althobaiti H. Chimeric Antigen Receptor T-Cells: An Overview of Concepts, Applications, Limitations, and Proposed Solutions. Front Bioeng Biotechnol 2022;10:797440. [DOI: 10.3389/fbioe.2022.797440] [Reference Citation Analysis]
97 He Y, Vlaming M, van Meerten T, Bremer E. The Implementation of TNFRSF Co-Stimulatory Domains in CAR-T Cells for Optimal Functional Activity. Cancers (Basel) 2022;14:299. [PMID: 35053463 DOI: 10.3390/cancers14020299] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
98 Chen R, Jing J, Siwko S, Huang Y, Zhou Y. Intelligent cell-based therapies for cancer and autoimmune disorders. Curr Opin Biotechnol 2020;66:207-16. [PMID: 32956902 DOI: 10.1016/j.copbio.2020.08.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
99 Safarzadeh Kozani P, Safarzadeh Kozani P, Ahmadi Najafabadi M, Yousefi F, Mirarefin SMJ, Rahbarizadeh F. Recent Advances in Solid Tumor CAR-T Cell Therapy: Driving Tumor Cells From Hero to Zero? Front Immunol 2022;13:795164. [PMID: 35634281 DOI: 10.3389/fimmu.2022.795164] [Reference Citation Analysis]
100 Marofi F, Rahman HS, Thangavelu L, Dorofeev A, Bayas-Morejón F, Shirafkan N, Shomali N, Chartrand MS, Jarahian M, Vahedi G, Mohammed RN, Shahrokh S, Akbari M, Khiavi FM. Renaissance of armored immune effector cells, CAR-NK cells, brings the higher hope for successful cancer therapy. Stem Cell Res Ther 2021;12:200. [PMID: 33752707 DOI: 10.1186/s13287-021-02251-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
101 Marofi F, Tahmasebi S, Rahman HS, Kaigorodov D, Markov A, Yumashev AV, Shomali N, Chartrand MS, Pathak Y, Mohammed RN, Jarahian M, Motavalli R, Motavalli Khiavi F. Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism. Stem Cell Res Ther 2021;12:217. [PMID: 33781320 DOI: 10.1186/s13287-021-02283-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
102 Jin Y, Dong Y, Zhang J, Sun J, Liu Y, Chen Y. The toxicity of cell therapy: Mechanism, manifestations, and challenges. J Appl Toxicol 2021;41:659-67. [DOI: 10.1002/jat.4100] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
103 Lesch S, Benmebarek MR, Cadilha BL, Stoiber S, Subklewe M, Endres S, Kobold S. Determinants of response and resistance to CAR T cell therapy. Semin Cancer Biol 2020;65:80-90. [PMID: 31705998 DOI: 10.1016/j.semcancer.2019.11.004] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
104 Zhang C, Zhuang Q, Liu J, Liu X. Synthetic Biology in Chimeric Antigen Receptor T (CAR T) Cell Engineering. ACS Synth Biol 2022;11:1-15. [PMID: 35005887 DOI: 10.1021/acssynbio.1c00256] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
105 Ravasio S. Industrial Perspective on Immunotherapy. Adv Exp Med Biol 2021;1295:327-47. [PMID: 33543467 DOI: 10.1007/978-3-030-58174-9_15] [Reference Citation Analysis]
106 Hamilton G, Plangger A. The Impact of NK Cell-Based Therapeutics for the Treatment of Lung Cancer for Biologics: Targets and Therapy. Biologics 2021;15:265-77. [PMID: 34262255 DOI: 10.2147/BTT.S290305] [Reference Citation Analysis]
107 Halama N. The next age of immunotherapy: optimisation, stratification and therapeutic synergies. Br J Cancer 2019;120:1-2. [PMID: 30413823 DOI: 10.1038/s41416-018-0330-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]